We provide further evidence that screening for the presence of IDH1‐ and IDH2‐mutant molecules in plasma from patients with central cartilaginous tumours leads to a more accurate grade and prognosis, when interpreted in the context of imaging and anatomical site, than currently provided. This evidence concerns the gene IDH1 and neoplasm.